Experience and Leadership that Goes Beyond Cancer

The management team has deep experience in oncology as well as the safe and effective delivery of nitric oxide–based therapy. Chief Executive Officer Selena Chaisson, MD, brings unparalleled management experience from the finance sector, including 15 years as Director of Healthcare Investments at Bailard, Inc. In addition, they will leverage the expertise at Beyond Air which has already proven the ability to safely harness the power of nitric oxide to treat respiratory disease.

At the patient level, our goal is to provide cancer patients and their families with the confidence that their disease will not recur or metastasize. On a global scale, we are poised to potentially reduce a leading cause of death—cancer.1,2

We are redefining the cancer treatment experience by relieving the tremendous burden that cancer places on individuals, families, communities, and health systems.

Illustration of Nitric Oxide Molecules

Proven Business Record and Clinical Experience in Oncology and Nitric Oxide


Selena Chaisson, MD

Selena Chaisson, MDChief Executive Officer & Director

Before joining Beyond Cancer as Chief Executive Officer, Selena Chaisson was the Director of Healthcare Investments at Bailard, where she focused on highly specialized, emerging healthcare opportunities for 16 years. Prior to Bailard, she held senior executive roles at RCM Capital Management and Tiger Management. RCM Capital Management was acquired and then merged with Allianz Global Investors U.S. in 2013.

Selena received a BS in Microbiology in 1987 from Louisiana State University in Baton Rouge, LA, where she graduated summa cum laude. She earned her MBA and MD from Stanford University in 1992 and 1993, respectively.

Hila Confino

Hila ConfinoChief Scientific Officer

Hila Confino joined Beyond Cancer in 2021 as Chief Scientific Officer from Beyond Air, where she served as Head of Research in Israel. At Beyond Air, Hila led the oncology preclinical team and conducted in vitro and in vivo studies for ultra-high concentration nitric oxide in solid tumors.

Hila has over 12 years of experience in cancer immunology research in both the academic and industry settings. Her work has been featured at numerous scientific conferences and published in multiple peer-reviewed journals. She holds a Ph.D. and Master of Science in Cancer Immunology from Tel Aviv University. Hila received a BS in Biotechnology from Bar—Ilan University in Israel, where she graduated cum laude.

Jedidiah Monson, M.D

Jedidiah Monson, M.DChief Medical Officer

Dr. Monson, a founding partner of cCARE in 2008, oversaw its growth into the largest private practice oncology group in the state of California with a focus on research and excellence in clinical care. In April 2022, cCARE merged with Integrated Oncology Network (ION) resulting in a nationwide oncology and healthcare management group, with a presence in 57 oncology centers across 14 states. He has previously held staff positions at the City of Hope National Medical Center, Valley Radiotherapy Associates, and 21st Century Oncology.

In addition, Dr. Monson is a member of the American College of Radiology and the American Society of Therapeutic Radiology & Oncology. Dr. Monson earned his M.D. from Stanford University School of Medicine and completed his radiation oncology residency at the Joint Center for Radiation Therapy at Harvard Medical School. During his residency, he received an M.P.H from the Harvard School of Public Health.

Susan Howell Jones

Susan Howell JonesChief Financial Officer

Susan Howell Jones joins Beyond Cancer with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid.

Following her tenure at BASF, Susan joined Summit Agro USA, LLC, a start-up and subsidiary of Sumitomo Corp., as Chief Financial Officer. Most recently she served as Interim Chief Financial Officer at dPIX, LLC, a semiconductor producer for medical and aerospace industries. She began her career in the public accounting sector working with Deloitte and Touche, LLC. 

Board of Directors

Steve Lisi

Steve LisiChairman of the Board

Since 2017, Steve has served as CEO and Chairman of the Board of Beyond Air (XAIR). He brings to Beyond Cancer 18 years of experience as a healthcare investor and 9 years as a healthcare executive with positions of Chief Executive Officer and SVP, Head of Strategy and Business Development.

Selena Chaisson, MD

Selena Chaisson, MDChief Executive Officer & Director

Selena brings to Beyond Cancer her experience of 16 years as Head of Healthcare Investments at Bailard managing the Emerging Life Science strategy and more than 25 years as a healthcare investor overall. She earned her MBA and MD from Stanford University.

Amir Avniel

Amir AvnielExecutive Director

As Chief Operating Officer and Cofounder of Beyond Air (XAIR), Amir brings more than 20 years of executive-level experience in finance, business development, and operations—including mergers and acquisitions—to Beyond Cancer.

Robert F. Carey

Robert F. CareyDirector

Bob has been a board member at Beyond Air (XAIR) since February of 2019. His 30+ years of healthcare industry experience include positions such as Cofounder, President, and Chief Operations Officer of ACELYRIN; Executive Vice President and Chief Business Officer at Horizon; and Managing Director and Head of Healthcare Investment Banking at JMP Securities.

David Dvorak

David DvorakDirector

David brings over 30 years of healthcare executive experience leading global medical device companies. He served at Zimmer Biomet Holdings as President and CEO and led the acquisition and integration of Biomet in 2014. His prior experience includes executive officer with STERIS Corporation, the Board of Directors of St. Jude Medical, Inc., the Advanced Medical Technology Association, and the Orthopaedic Research and Education Foundation.

Greg Berk, MD

Greg Berk, MDDirector

Greg has 30+ years of oncology drug development experience, currently serving as President of R&D and CMO of GT Biopharma. Prior experience includes CMO of Celularity, executive roles at Verastem, Sideris Pharmaceuticals, BIND Therapeutics, Abraxis BioScience, Intellikine, and served on the integration leadership team during the Celgene acquisition of Abraxis in 2010.

References: 1. Cancer. World Health Organization. March 3, 2021. Accessed September 14, 2021. https://www.who.int/news-room/fact-sheets/detail/cancer; 2. Cancer. World Health Organization. Accessed September 14, 2021. https://www.who.int/health-topics/cancer

A Cancer Treatment with a Powerful Systemic Response

Our Approach